XBRANE BIOPHARMA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.283 SEK | -3.08% |
|
+26.00% | -97.16% |
| May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
| May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
Presenter SpeechAnette Lindqvist (Executives)Good afternoon, everybody and good morning to any...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
2024-07-17
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.292
SEK
Average target price
0.625
SEK
Spread / Average Target
+114.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -97.16% | 42.35M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +36.61% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB - Special Call
